trending Market Intelligence /marketintelligence/en/news-insights/trending/DkO9jM5r6RscVOhejQ0Pxw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer Q4'16 adjusted income narrows YOY

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pfizer Q4'16 adjusted income narrows YOY

Pfizer Inc. saw its fourth-quarter 2016 adjusted income decline year over year, though full-year results were an increase on those recorded in 2015.

Fourth-quarter 2016 adjusted income was down 12% to $2.89 billion, or 47 cents per share, from $3.31 billion, or 53 cents per share, in the closing months of 2015.

The S&P Capital IQ normalized EPS consensus estimate for the fourth quarter was 51 cents.

Pfizer posted reported net income of $775 million, or 13 cents per share, for the fourth quarter of 2016, compared to a loss of $172 million, or 3 cents per share, in the 2015 fourth quarter.

Fourth-quarter 2016 revenues were down 3% year over year to $13.63 billion.

For the year, Pfizer posted $14.76 billion, or $2.40 per share, in adjusted income, an increase from $13.76 billion, or $2.20 per share, in 2015. Reported net income also increased to $7.22 billion, or $1.17 per share, from $6.96 billion, or $1.11 per share, in 2015.

The S&P Capital IQ normalized EPS consensus estimate for 2016 was $2.41.

Pfizer's full-year 2016 revenues were up 8% year over year to $52.82 billion.

The company expects to see $2.50 to $2.60 in adjusted EPS during 2017. The S&P Capital IQ normalized EPS consensus estimate for 2017 is $2.56.